Drug Discovery

Orgenesis to acquire regenerative medicine company Koligo Therapeutics

Biotechnology company Orgenesis has signed an agreement to acquire US-based regenerative medicine company Koligo Therapeutics.

Permira funds to acquire European CNS specialty pharmaceutical company Neuraxpharm

Permira, the global private equity firm, today announced that a company backed by the Permira funds has agreed to acquire Neuraxpharm, a leading European specialty pharmaceutical company focused on the treatment of the central nervous system (CNS) from funds advised by Apax Partners.

OnKure, Pfizer collaborate to evaluate combination of OKI-179 and binimetinib

OnKure, a leader in discovery and development of next generation histone deacetylase (HDAC) inhibitors, entered into a clinical trial collaboration and supply agreement with Pfizer to support the clinical proof of concept study for MEKTOVI (binimetinib) in combination with OKI-179, a highly potent and tolerable Class I HDAC inhibitor currently in Phase I for the treatment of NRAS melanoma.

Roche acquires Irish biotechnology company Inflazome for €380m

Swiss drugmaker Roche has completed a share purchase agreement to acquire an Irish biotechnology company Inflazome for an upfront payment of €380m.

AstraZeneca acquires Dogma’s oral PCSK9 inhibitor programme

AstraZeneca has acquired a preclinical oral PCSK9 inhibitor programme from Dogma Therapeutics for an undisclosed price.

Moderna, Chiesi collaborate to develop mRNA therapeutics for pulmonary arterial hypertension

Moderna, a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients and Chiesi Farmaceutici S.p.A., an international research-focused healthcare group (Chiesi Group), announced a collaboration aimed at the discovery and development of mRNA therapeutics for the treatment of pulmonary arterial hypertension (PAH), a rare disease with an incidence of 2-5 per million adults.

Takeda inaugurates new R&D cell therapy manufacturing facility in US

Takeda Pharmaceutical has opened a new 24,000ft² research and development (R&D) therapy manufacturing facility in Massachusetts, US.

HiFiBiO, ABL Bio to co-develop HFB30132A antibody for Covid-19

HiFiBiO Therapeutics has entered into a partnership with South Korea-based ABL Bio to co-develop its SARS-CoV-2 neutralising antibody HFB30132A for the treatment of Covid-19.

Merck to purchase $1bn equity stake in Seattle Genetics

Drug-maker Merck has announced the acquisition of a $1bn equity stake in biotechnology company Seattle Genetics.